Retatrutide
Triple agonist at GLP-1R, GIPR and GCGR. The gGlu-C20 fatty-diacid arm drives albumin binding, which is what separates its kinetics from the native ligands.
Before you begin
- • Lot-matched certificate and laboratory notebook
- • Calibrated pipettes, low-binding tubes and suitable PPE
- • Validated solvent, assay reagents and model-specific SOP
- • Appropriate positive, negative and vehicle controls
Required controls
- Vehicle-only negative control
- Matched receptor-null cell line
- Validated reference agonist
- Untreated viability control
Reported protocol
- Initial phase (weeks 1-4)
- 1.0 mg to 2.0 mg once weekly
- Intermediate phase
- 4.0 mg once weekly
- Target maintenance
- 8.0 mg to 12.0 mg once weekly
- Route
- Subcutaneous
Diluent
Sterile bacteriostatic water (0.9% benzyl alcohol) for multi-withdrawal stock, or sterile water for injection where a preservative-free stock is required by the assay.
Compound-specific: Use bacteriostatic or sterile water only. Sodium-chloride-containing diluents are not a validated solvent for this lipidated, acetate-buffered material and have been associated with cloudiness and precipitation. A vial that goes cloudy on addition of solvent should be discarded, not filtered and used.
Reconstitution concentrations
Solvent volume sets the stock concentration. Lower volume gives a more concentrated stock and smaller working aliquots; higher volume gives a more dilute stock that is easier to measure accurately. Figures differ by vial size — use the table for the size you have.
20 mg vial
| Solvent added | Stock concentration | Per 0.1 mL | Per unit (U-100) |
|---|---|---|---|
| 1 mL | 20 mg/mL | 2 mg | 200 mcg |
| 2 mL | 10 mg/mL | 1 mg | 100 mcg |
| 3 mL | 6.67 mg/mL | 666.67 mcg | 66.67 mcg |
10 mg vial
| Solvent added | Stock concentration | Per 0.1 mL | Per unit (U-100) |
|---|---|---|---|
| 1 mL | 10 mg/mL | 1 mg | 100 mcg |
| 2 mL | 5 mg/mL | 500 mcg | 50 mcg |
| 3 mL | 3.33 mg/mL | 333.33 mcg | 33.33 mcg |